Vaccine Development
Human testing of novel vaccine to fight nicotine addiction begins
Published in Vaccine Weekly, July 17th, 2002
Nabi Biopharmaceuticals (NABI) has initiated NicVAX (nicotine conjugate vaccine) phase I testing in humans. NicVAX is a proprietary and novel investigational vaccine designed to help the body develop antibodies that bind to nicotine and block it from reaching the brain. If shown to be safe and effective in subsequent clinical trials, NicVAX may help millions of people worldwide kick their addiction to cigarettes and tobacco products.
Of the 48 million adult U.S. smokers, about 70%, or nearly 34 million people have made at least one attempt to stop, yet only 1.2 million quit permanently, according to the U.S. Centers for Disease Control and Prevention.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2002-07-17)
More Articles from Vaccine Weekly
- Vaccination
Influenza vaccination reduces risk of adverse cardiac events during flu season - Vaccine Development
Conjugated CD20 vaccine elicits specific, polyclonal immune response in mice - Hepatitis B Vaccine
Waiting to vaccinate against hepatitis B may be best policy for preterm infants - Vaccine Development
Novel Leishmania donovani protein potential vaccine antigen - Vaccine Development
Proteomic methods promising for antigen identification - Vaccine Development
Therapeutic HPV vaccine shows promise - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
